Travel Vaccines Market Report 2025

The travel vaccines market size has grown strongly in recent years. It will grow from $4.73 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased international travel, government initiatives for travel health, globalization of diseases, growing awareness among travelers, and expansion of the travel and tourism industry.

The travel vaccines market size is expected to see strong growth in the next few years. It will grow to $7.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing frequency of business travel, emerging infectious disease threats, government regulations and entry requirements, rising demand for exotic destinations, and collaboration between governments and pharmaceutical companies. Major trends in the forecast period include tailored vaccination strategies, expansion of the market to non-endemic regions, adoption of digital health technologies, regulatory support, and streamlined approvals, innovative developments.

The anticipated surge in travel and tourism is poised to drive the expansion of the travel vaccine market in the future. Travel and tourism encompass the movement of people and vehicles across various distant geographic areas, including trains, boats, airplanes, and other modes of transportation. Travel vaccines play a crucial role in ensuring the safety and health of tourists and travelers during their journeys abroad. As of January 2023, the United Nations World Tourism Organization (UNWTO) reported that over 900 million tourists ventured abroad in 2022, marking a twofold increase from the previous year and a substantial 63% rise from pre-pandemic levels. This surge in travel and tourism is a significant factor propelling the growth of the travel vaccine market.

The growth of the travel vaccine market is being driven by the increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending includes investments in travel vaccines as a preventive measure, which helps reduce the economic burden associated with treating travel-related diseases. Travel vaccines play a vital role in public health by minimizing the risk of infectious diseases during international travel, thereby avoiding costs related to medical treatment, hospitalization, and potential outbreaks upon return. For example, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, with projected spending expected to rise to between $605 and $635 billion by 2025. Therefore, the increase in healthcare spending is propelling the growth of the travel vaccine market moving forward.

Product innovation stands out as a prominent trend gaining traction in the travel vaccine market, with major companies actively pursuing the development of innovative vaccines to strengthen their market positions. For example, in August 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, received approval for QDENGA (Dengue Tetravalent Vaccine) (TAK-003) from the Indonesia National Agency for Drug and Food Control. QDENGA, designed for the prevention of dengue sickness in individuals aged six to 45, demonstrated sustained overall protection against dengue sickness and hospitalization three years after immunization, regardless of prior exposure to the disease.

Major companies operating in the travel vaccine market are developing innovative vaccines to provide active immunization to prevent Hepatitis A common concern for travelers. A travel vaccine is a vaccine specifically designed to protect individuals from infectious diseases that are prevalent in certain regions or countries, often recommended for travelers visiting those areas. For instance, in January 2024, Indian Immunologicals Ltd. (IIL), an India-based biotechnology company, launched Havisure, India’s first indigenously developed Hepatitis A vaccine. Havisure is anticipated to be instrumental in providing protection against the Hepatitis A virus, which mainly impacts the liver. This vaccine is effective in preventing the disease and is advised for children as part of routine immunization. Additionally, it is recommended for individuals at risk of exposure or those traveling to areas with high rates of hepatitis A.

In May 2023, Bavarian Nordic, a US-based biopharmaceutical company, acquired Emergent BioSolutions' travel vaccine portfolio for an undisclosed amount. This strategic acquisition includes two commercially available vaccines - Vivotif for preventing typhoid fever and Vaxchora for cholera prevention - as well as a Phase 3 vaccine candidate targeting the prevention of the Chikungunya virus. The deal also encompasses R&D facilities in the US, a Swiss biologics production facility, and EU and US commercial operations with a specialized salesforce. Emergent BioSolutions, a US-based biotechnology firm, specialized in manufacturing devices, vaccines, and therapeutics, with its travel vaccine division being part of the acquisition.

Major companies operating in the travel vaccines market include Pfizer Inc., Johnson and Johnson, Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Biological E. Limited, Takeda Pharmaceutical Company Limited, Novavax Inc., Emergent BioSolutions UK, Serum Institute of India Pvt. Ltd., Dynavax Technologies, Bavarian Nordic A/S, Valneva SE, Panacea Biotec, Vabiotech, Inovio Pharmaceuticals, Bharat Biotech International Limited, Altimmune Inc., Bio Farma, Vaxart Inc.

North America was the largest region in the travel vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the travel vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the travel vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Travel vaccines are immunizations designed to protect against diseases prevalent in either the country of origin or the destination. Their purpose is to ensure the well-being of travelers and prevent the transmission of diseases within and between nations.

The primary travel vaccines targeting various diseases include hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Hepatitis A is caused by the hepatitis A virus (HAV), leading to liver inflammation. These vaccines are available as mono vaccines or combination vaccines and can be booked through online and in-person channels for domestic travel, as well as through outbound travel applications.

The travel vaccine market research report is one of a series of new reports that provides travel vaccine market statistics, including the travel vaccine industry global market size, regional shares, competitors with a travel vaccine market share, detailed travel vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the travel vaccine industry. This travel vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The travel vaccine market consists of sales of vaccines for diseases such as Japanese encephalitis, tick-borne encephalitis, and tuberculosis (TB). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.